In a new interview with Biostock, Chordate CEO Anders Weilandt talks about the recently completed rights issue, how the capital will be utilized and what strategic initiatives are planned moving forward.
“We are now fully focused on supporting the exit process, which means we are not prioritising costs that have a long-term effect horizon. Any costs that do not have a direct impact on the potential for a successful transaction will have to wait”, says Anders Weilandt to Biostock.
What concrete initiatives are you planning to increase the chances of an exit?
– Primarily, we aim to obtain more positive market validation from our key focus markets: Finland, Germany, Switzerland, Italy, and Saudi Arabia. Following that, the completion of the two ongoing migraine studies will be a priority. Overall, these are efforts that we believe will positively impact a successful exit outcome.
What are your three strongest arguments for an entity considering acquiring the company’s operations and the Ozilia treatment?
– First, the ability to add a well-patented, scientifically proven, and drug-free alternative to their product portfolio.
– Secondly, acquiring a de-risked, scalable, and fully developed treatment technology that can be seamlessly integrated into their own sales organisation.
– Finally, Chordate’s operations are relatively easy to acquire and integrate into an existing business and production structure.
